
Lawsuit probes Iovance after lung cancer trial data revision causes 35% stock drop
Pomerantz LLP is investigating Iovance Biotherapeutics for potential securities fraud following a revision in its lung cancer trial results. Initially reported as "Positive," the Phase 2 trial data was later described as "Consistent with Previously R...


